# Potential Protective Effects of Naloxone in Traumatic Brain Injury Through JAK2/STAT3 Signaling Modulation

**Authors:** Dong Hyuk Youn, Harry Jung, Ji Hyeon Lee, Seongwon Pak, Sung Woo Han, Jong-Tae Kim, Kang Song, Hae Ryong Choi, Gui Seung Han, Young-Suk Kwon, Jeong Jin Park, Jin Pyeong Jeon, Jae Jun Lee, Jong-Kook Rhim

PMC · DOI: 10.3390/life16030480 · 2026-03-16

## TL;DR

Naloxone may help protect the brain after injury by reducing inflammation and improving cognitive function through a specific signaling pathway.

## Contribution

Naloxone's neuroprotective effects in TBI are linked to JAK2/STAT3 signaling modulation.

## Key findings

- Naloxone reduced brain swelling and tissue loss in TBI mice.
- Naloxone improved cognitive performance in TBI mice.
- Naloxone modulated JAK2/STAT3 signaling and reduced oxidative stress.

## Abstract

Background: We evaluated the potential neuroprotective effects of naloxone in moderate traumatic brain injury (TBI), focusing on its ability to alleviate neuroinflammation, reduce cognitive impairment, and to influence Janus tyrosine kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling markers. Methods: Male C57BL/6J mice were used to establish an in vivo model of moderate TBI using a stereotaxic impactor. Immediately post-injury, naloxone was administered intraperitoneally (1 mg/kg/day) for 7 days. A total of 72 mice were divided into four groups: Normal, normal with naloxone, TBI, and TBI with naloxone (18 mice in each group). Immunohistochemical analyses and cognitive functions were evaluated across the groups. Results: TBI mice treated with naloxone exhibited significantly reduced brain swelling and cortical tissue loss compared to untreated mice. Naloxone reduced Transforming growth factor beta 2 (TGF-β2) and increased interleukin 11 (IL-11) expression in the brain. Additionally, levels of JAK2, STAT3, and B-cell lymphoma 2 (Bcl-2) were significantly elevated following treatment, while expressions of Tumor protein p53 (p53), Caspase 3, Microtubule-associated proteins 1A/1B light chain 3B (LC3B), and Sequestosome 1 (p62) were reduced. Fluorescence intensities of ionized calcium binding adaptor molecule (Iba-1) and dichloro-dihydro-fluorescein diacetate (DCFH-DA) were enhanced, indicating decreased microglial activation and reactive oxygen species (ROS) production due to naloxone treatment. Cognitive function tests revealed improved performance in TBI mice treated with naloxone, demonstrated by decreased alteration rates in the Y-maze test and improved preference index scores in the novel object recognition (NOR) test. Conclusions: Naloxone shows potential for neuroprotection and enhanced cognitive performances, which may be associated with modulation of JAK2/STAT3 signaling in a mouse model of moderate TBI.

## Linked entities

- **Genes:** JAK2 (Janus kinase 2) [NCBI Gene 3717], STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774], BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596], TP53 (tumor protein p53) [NCBI Gene 7157], MAP1LC3B (microtubule associated protein 1 light chain 3 beta) [NCBI Gene 81631], GTF2H1 (general transcription factor IIH subunit 1) [NCBI Gene 2965], AIF1 (allograft inflammatory factor 1) [NCBI Gene 199], TGFB2 (transforming growth factor beta 2) [NCBI Gene 7042], IL11 (interleukin 11) [NCBI Gene 3589]
- **Chemicals:** naloxone (PubChem CID 4425), DCFH-DA (PubChem CID 104913)
- **Diseases:** traumatic brain injury (MONDO:0858950)

## Full-text entities

- **Genes:** Iba1 (induction of brown adipocytes 1) [NCBI Gene 114737], Casp3 (caspase 3) [NCBI Gene 12367] {aka A830040C14Rik, AC-3, CASP-3, CC3, CPP-32, CPP32}, Bcl2 (B cell leukemia/lymphoma 2) [NCBI Gene 12043] {aka Bcl-2, C430015F12Rik, D630044D05Rik, D830018M01Rik}, Il11 (interleukin 11) [NCBI Gene 16156] {aka IL-11}, Jak2 (Janus kinase 2) [NCBI Gene 16452] {aka Fd17}, Map1lc3b (microtubule-associated protein 1 light chain 3 beta) [NCBI Gene 67443] {aka 1010001C15Rik, Atg8, LC3b, MAP1A/MAP1B, Map1lc3}, Trp53-ps (transformation related protein 53, pseudogene) [NCBI Gene 22060], Tgfb2 (transforming growth factor, beta 2) [NCBI Gene 21808] {aka Tgf-beta2, Tgfb-2}, Sqstm1 (sequestosome 1) [NCBI Gene 18412] {aka A170, OSF-6, Osi, STAP, STONE14, p62}, Stat3 (signal transducer and activator of transcription 3) [NCBI Gene 20848] {aka 1110034C02Rik, Aprf}
- **Diseases:** cognitive impairment (MESH:D003072), neuroinflammation (MESH:D000090862), TBI (MESH:D000070642), brain swelling (MESH:D001929), tissue loss (MESH:D017695), Tumor (MESH:D009369)
- **Chemicals:** Naloxone (MESH:D009270), calcium (MESH:D002118), dichloro-dihydro-fluorescein diacetate (-), ROS (MESH:D017382), DCFH-DA (MESH:C029569)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13027423/full.md

---
Source: https://tomesphere.com/paper/PMC13027423